This preclinical transgenic model holds significant promise for screening potential small molecules acting as agonists or antagonists of ERα, and therefore could expedite the development of alternative therapeutic agents to treat tamoxifen-resistant breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.